Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it has appointed Patrick O’Brien as General Counsel. In this role, Mr. O’Brien will have overall responsibility to manage all of the Company’s legal matters.

“Patrick will be an integral part of the Arrowhead management team,” said Christopher Anzalone, Ph.D., Arrowhead’s President and Chief Executive Officer. “His twenty year history of representing and advising biopharmaceutical companies from multiple vantage points will be a great asset as we move forward.”

Mr. O’Brien comes to Arrowhead from Shire where he served as Group Vice President, Legal in Shire’s Boston office. Prior to that, he was Chief Legal Officer for Shire’s regenerative medicine division. Mr. O’Brien has also served as Assistant General Counsel for Johnson & Johnson and Vice President, Law of its Centocor Ortho-Biotech business unit, Regulatory Counsel at the U.S. Food and Drug Administration, and as outside counsel to biopharmaceutical high technology companies while engaged in private practice. He holds B.S. in Pharmacy, Pharm.D., and J.D. degrees from the University of Arizona.

About Arrowhead Research Corporation

Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary Dynamic Polyconjugate delivery platform to develop targeted drugs based on the RNA interference mechanism that efficiently silences disease-causing genes. Arrowhead’s pipeline includes ARC-520 for chronic hepatitis B virus, ARC-AAT for liver disease associated with Alpha-1 antitrypsin deficiency, and partner-based programs in obesity and oncology.

For more information please visit http://www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadresearch.com/alerts.cfm.

NASDAQ Notice

As an inducement to entering into employment with the Company, on December 2, 2014, new employees of the Company were awarded an "inducement" grant of options and restricted stock units (RSU) under Rule 5635(c)(4) of the NASDAQ Marketplace Rules. The option entitles the new employees to purchase, outside of the Company's stockholder approved equity incentive plans, an aggregate of up to 120,000 shares of the Company's common stock at an exercise price per share of $5.22, the last reported closing price of the Company's common stock on the date of grant and 30,000 restricted stock units. The option vests and becomes exercisable over a period of four years from the date of grant and the RSUs vest annually in three equal installments.

Source: Arrowhead Research Corporation

Arrowhead Research CorporationVince Anzalone, CFA626-304-3400ir@arrowres.comorInvestor Relations:The Trout GroupLauren Glaser646-378-2972ir@arrowres.comorMedia:Russo PartnersMartina Schwarzkopf, Ph.D.212-845-4292martina.schwarzkopf@russopartnersllc.com

Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Arrowhead Pharmaceuticals Charts.
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Arrowhead Pharmaceuticals Charts.